Table 2.
Group (Smokers vs. Control Subjects) and Drug Condition (Smokers+NIC vs. Smokers+PBO) Effects on Activity Associated with Trial Valence, Magnitude, and Outcome
| Talairach Coordinates |
||||||||
|---|---|---|---|---|---|---|---|---|
| Comparison (Drug/Group) |
Stimulus | Effect | Region | x | y | z | KE | Contrasta |
| Smokers+NIC vs. Smokers+PBO | Valence (Prime 1) | Drug conditionb | Right putamen | 24 | −4 | 4 | 38 | Nicotine < placebo |
| Outcome | Drug X outcomec | Left middle frontal gyrus | 28 | 15 | 53 | 249 | Nicotine: successful > unsuccessful Placebo: NS | |
| Controls vs. Smokers+NIC | Valence (Prime 1) | Groupb | Right SFG/BA 10 | 13 | 66 | 10 | 34 | Smokers < control subjects |
| Valence (Prime 1) | Groupb | Left NAcc | −13 | 10 | −8 | 28 | Smokers < control subjects | |
| Gain magnitude (Prime 2) | Groupb | Left caudate | −7 | 6 | 6 | 48 | Smokers > control subjects | |
| Loss magnitude (Prime 2) | Groupb | Left caudate | −10 | 1 | 14 | 55 | Smokers > control subjects | |
| Outcome | Group X outcomec | Left cingulate and BA 31 | −2 | −37 | 36 | 693 | Smokers: successful > unsuccessful control subjects: NS | |
| Controls vs. Smokers+PBO | Valence (Prime 1) | Groupb | Right ACC/BA 32 | 4 | 38 | −7 | 68 | Smokers < control subjects |
ACC, anterior cingulate cortex; BA, Brodmann’s area; KE, cluster extent (mm3); NAcc, nucleus accumbens; +NIC, postnicotine; NS, non significant; +PBO, postplacebo; SFG, superior frontal gyrus.
a
Significant at pCORRECTED < 0.05.
b
Small volume correction.
c
Whole-brain analysis.